Thyroid Gland Medullary Carcinoma

I travel to MDA from Louisville, KY several times a year for medullary thyroid cancer monitoring and lung & breast cancer follow up. MDA is the most amazing place. I couldn’t ask for a better patient experience. Job well done, Dr. Frumovitz. Sending positive vibes your way. (@gerber2012)

Medullary thyroid carcinoma with Dr. Jung #endoPath #USCAP23 #USCAP2023 (@menamansour)

Like we remember imp bus numbers, remember 2 most imp codons of #RET gene mutation Codon 918 cause most aggressive #MedullaryThyroidCancer & characteristic #MEN2B phenotype Codon 634 cause aggressive MTC & #MEN2A syndrome For other codons check their cancer risk before you act (@RajivSarin5)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @andreevdrakhlin https://t.co/2m3BXONoLn (@VivekSubbiah)

Fascinating, does Merkels have more SSTR-2? Maybe PRRT should be tried in a bunch of tumors with high SSTR expression- pheochromocytoma, paraganglioma, medullary thyroid cancer even small cell lung carcinoma ? (@RenoHemonc)

. @VivekSubbiah thoughts on KRAS-mutated Medullary Thyroid Cancer being a candidate for this approach? https://t.co/CUWZCbqPuV (@caseyrcrowe)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @JCOPO_ASCO @andreevdrakhlin @OncoAlert https://t.co/khTk21IHMq (@VivekSubbiah)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @JCOPO_ASCO @OncoAlert https://t.co/bOKRhstki1 (@VivekSubbiah)

⭐️Systemic & CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases 🎯🧬#PrecisionMedicine @JCOPO_ASCO @andreevdrakhlin @OncoAlert https://t.co/lTc9gigW9u (@VivekSubbiah)

On behalf of Dr. Zubair Baloch @aakasharmand at #USCAP2022. Medullary thyroid carcinoma grading #EndoPath #USCAP22 #MTC #Ki67 (@edusqo)

💫Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial @OncJournal @OncoAlert #thycsm https://t.co/uvDzeEb8l2 (@VivekSubbiah)

Over 40% of patients with RET-mutant MTC who received selpercatinib, a highly selective RET inhibitor, reported clinical meaningful improvements in diarrhea in a phase I/II study. (@VivekSubbiah)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @JCOPO_ASCO @andreevdrakhlin https://t.co/ZKtdfQ3l8x (@VivekSubbiah)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @RETpositive @ASCO_pubs @OncoAlert https://t.co/qT7qVo27Gb (@VivekSubbiah)

In addition, they have shown activity against somatic (60%–90%) or germline (100%) RET mutations seen in medullary thyroid cancer (@VivekSubbiah)

Over 40% of patients with RET-mutant Thyroidcancer on selpercatinib, reported clinical meaningful improvements in diarrhea Patient‐Reported Outcomes with Selpercatinib & RET‐Mutant Medullary Thyroid Cancer @OncJournal #TumorBoardTuesday https://t.co/NFHfuhfeIB (@VivekSubbiah)

RET fusions are seen in NSCLC (2%) and papillary thyroid cancers (PTC; 10%–20%), whereas somatic (60%–90%) or germline (100%) RET mutations are seen in medullary thyroid cancer (@VivekSubbiah)

Over 40% of patients with RET-mutant MTC who received selpercatinib, a highly selective RET inhibitor, reported clinical meaningful improvements in diarrhea in a phase I/2 study. (@VivekSubbiah)

⭐️RET fusions➡️2% -lung cancer, ~20% papillary thyroid cancer, <1% multiple cancers. ⭐️RET mutations➡️Medullary thyroid cancer 60 % sporadic,100%hereditary #Selpercatinib & #Pralsetinib Selective RET inhibitors @trendscancer @CellPressNews https://t.co/cxDhYhMVce (@VivekSubbiah)

🔺RET fusions👉 2% -lung cancer, ~20% papillary thyroid cancer, <1% multiple cancers. 🔺RET mutations👉Medullary thyroid cancer 60 % sporadic,100%hereditary 🔺#Selpercatinib & #Pralsetinib 👉selective RET inhibitors @trendscancer 🔺Questions for future https://t.co/cxDhYhMVce (@VivekSubbiah)

⭐️RET fusions ➡️2% -lung cancer & ~20% papillary thyroid cancer & multiple cancers. ⭐️RET mutations➡️Medullary thyroid cancer 60 % sporadic,100%hereditary. ⭐️#Selpercatinib & #Pralsetinib are novel selective RET inhibitors @trendscancer #PrecisionMedicine https://t.co/cxDhYhMVce (@VivekSubbiah)

New FDA Approval for RET Positive Medullary #ThyroidCancer @VivekSubbiah, clinical trials and Physician Investigator at @MDAndersonNews, discusses the results of the clinical trial that resulted in the approval of pralsetinib (Gavreto): https://t.co/0IEdoKv2B6 (@PatientPower)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @ASCO_pubs @andreevdrakhlin https://t.co/XQR3PwPjLo (@VivekSubbiah)

LISTEN NOW: In this episode of #OncLiveOnAir, @omalleygynonc of @OSUCCC_James, discusses the prognosis of patients w/ RET fusion+ medullary thyroid cancer and next steps for RET inhibitors in the field. https://t.co/2AHDJsLKRl (@OncLive)

LISTEN NOW: In this episode of #OncLiveOnAir, @omalleygynonc of @OSUCCC_James, discusses the prognosis of patients w/ RET fusion+ medullary thyroid cancer and next steps for RET inhibitors in the field. Listen now: https://t.co/sa6HzLirxj (@OncLive)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @andreevdrakhlin @ASCO_pubs https://t.co/3RZhIXZEmo (@VivekSubbiah)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @ASCO_pubs @OncoAlert #JCOPO @andreevdrakhlin @DrMCabanillas https://t.co/DQdu1amIUi (@VivekSubbiah)

Good activity of selective RET inhibitor BOS172738 in RET-driven tumors, such as RET-fusion NSCLC & RET-mutated medullary thyroid carcinoma, presented during Developmental Therapeutics session at ASCO today. Really like Phase 1 trial where waterfall plots remind me of waterfalls (@schoffski)

#ASCO21 Update on the phase I/II ARROW trial of pralsetinib from Dr. @curijoey. Pralsetinib (BLU-667) was given accelerated approval by the FDA on December 1, 2020 for #RET fusion positive NSCLC or RET mutant medullary thyroid cancer. Pralsetinib given 400mg orally once daily. 🧵 (@StephenVLiu)

Highly target-specific next generation RET inhibitor BOS172738 showing good safety and impressive activity in RET-altered solid tumors such as RET-fusion non-small cell lung cancer, RET-mutated medullary thyroid cancer and others. Read Schöffski et al. https://t.co/Iixy0KEOTe (@schoffski)

@DrLoriWirth on novel agents for RET-mutated thyroid cancers. Some amazing recent developments, great news for patients with #medullary #thyroidcancer! @AmThyroidAssn @MarkZafereoMD @DrMCabanillas @amandaperl (@michaelyehmd)

Thioflavin T florescence in a nodule of medullary thyroid carcinoma. Either sporadic (nonhereditary) or familial (hereditary: caused by gain of function germline mutations in the RET gene) #PathTweet #HeadAndNeckPath @GeisingerPath @JMGardnerMD (@doc_interrupted)

A new drug recently approved by the FDA targets the RET gene that’s present in almost 90% of advanced medullary thyroid cancer patients. Our Dr. Vivek Subbiah shares what these patients should know: https://t.co/t1Y5t9SvIH @VivekSubbiah @PatientPower #ThyroidCancer #EndCancer (@MDAndersonNews)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases #RET #PrecisionMedicine @andreevdrakhlin @ASCO_pubs https://t.co/LTX0PJDov2 (@VivekSubbiah)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in RET-Mutant Medullary Thyroid Cancer CNS Metastases @andreevdrakhlin @ASCO_pubs @OncoAlert https://t.co/8SzaupyB8K (@VivekSubbiah)

#OncoAlert Pralsetinib (nee BLU-667) now approved for RET-mutant medullary thyroid cancer based on a cohort from the ARROW trial where RR was 60% (79% lasting 6m or more). Pralsetinib is already approved by @FDAOncology for RET-fusion positive NSCLC. https://t.co/q0Tnhs8b0U (@StephenVLiu)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @andreevdrakhlin https://t.co/6bJ1fZyAUT (@VivekSubbiah)

Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer https://t.co/VKkv8vy5Ht via @onclive (@VivekSubbiah)

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers | RR=69%, 1-yr PFS=82% in previously treated RET mutant medullary thyroid cancer. @NEJM https://t.co/ICoWRe3PO8 (@rbryanbell)